» Articles » PMID: 11099086

Oral Ciprofloxacin Vs. Intramuscular Ceftriaxone As Empiric Treatment of Acute Invasive Diarrhea in Children

Overview
Specialty Pediatrics
Date 2000 Dec 1
PMID 11099086
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Acute invasive diarrhea is a potentially serious condition in children. Because of the increasing resistance of enteric pathogens to commonly used oral antibiotics, intramuscular ceftriaxone has become the routine drug in the treatment of acute invasive diarrhea requiring an emergency visit in southern Israel. The inconvenience of this parenteral regimen created an increased need for oral pediatric formulations for the treatment of invasive diarrhea.

Objectives: To evaluate the efficacy and safety of a suspension formulation of ciprofloxacin in the treatment of acute invasive diarrhea in infants and children.

Patients And Methods: From July 1996 through December 1997, 201 evaluable children ages 6 months to 10 years (35% <1 year; 70% <3 years) presenting with acute invasive diarrhea at the Pediatric Emergency Room were randomized to receive either ciprofloxacin suspension (10 mg/kg twice a day + im placebo; n = 95) or im ceftriaxone (50 mg/kg/day + placebo suspension; n = 106) for 3 days in a double blind manner. Stool cultures for Shigella, Salmonella, Campylobacter spp. and diarrheagenic Escherichia coli were obtained on Days 1, 3, 4 to 5 and 21 +/- 5. Clinical response and safety were assessed on Days 1, 2, 3, 4 to 5 and 21 +/- 5.

Results: We isolated 127 pathogens from 121 (60%) patients: 73 (57%) Shigella; 23 (18%) Salmonella; 18 (14%) E. coli; and 13 (10%) Campylobacter. Overall bacteriologic eradication on Day 4 to 5 was 99% for Shigella, 77% for Salmonella and 77% for Campylobacter, with no difference between the 2 groups. Clinical cure or improvement was observed in 100 and 99% of the ciprofloxacin and ceftriaxone groups, respectively. Serum ciprofloxacin values determined on Day 3 of the treatment were higher in the majority of patients than were the MIC50 and MIC90 values for the Shigella and Salmonella spp. isolated. Possible drug-related adverse events occurred in 13 patients [ciprofloxacin, 8 (8%); ceftriaxone, 5 (4.7%)] and were mild and transient. Joint examination was normal during and after completion of therapy in all patients.

Conclusion: Oral ciprofloxacin was as safe and effective as intramuscular ceftriaxone for the empiric treatment of acute invasive diarrhea in ambulatory pediatric patients requiring an emergency room visit.

Citing Articles

Three Days of Oral Azithromycin Versus Five Days of Oral Clarithromycin in the Treatment of Campylobacter Enterocolitis in Children: A Prospective Study.

Kang H, Cho Y, Kim Y, Jeong D, Yoo I Antibiotics (Basel). 2024; 13(10).

PMID: 39452235 PMC: 11504726. DOI: 10.3390/antibiotics13100969.


Safety analysis of quinolones use in minors-based on the FAERS database.

Li Y, Wang J, Wang C, Chen L Front Med (Lausanne). 2024; 11:1437376.

PMID: 39267976 PMC: 11390674. DOI: 10.3389/fmed.2024.1437376.


Assessment of the risk of musculoskeletal adverse events associated with fluoroquinolone use in children: A meta-analysis.

Wang J, Cui H, Hu Y, Tang H Medicine (Baltimore). 2020; 99(34):e21860.

PMID: 32846837 PMC: 7447478. DOI: 10.1097/MD.0000000000021860.


Safety of ceftriaxone in paediatrics: a systematic review.

Zeng L, Wang C, Jiang M, Chen K, Zhong H, Chen Z Arch Dis Child. 2020; 105(10):981-985.

PMID: 32144089 PMC: 7513262. DOI: 10.1136/archdischild-2019-317950.


Seizures and quinolone antibiotics in children: a systematic review of adverse events.

Neame M, King C, Riordan A, Iyer A, Kneen R, Sinha I Eur J Hosp Pharm. 2020; 27(2):60-64.

PMID: 32133130 PMC: 7043247. DOI: 10.1136/ejhpharm-2018-001805.